Lilly forecasts weak sales of weight-loss drug, shares slump
Lilly forecasts weak sales of weight-loss drug, shares slump
January 14, 2025
Eli Lilly's stock dropped 8% after forecasting fourth-quarter sales of its weight-loss drug Zepbound below Wall Street estimates, marking the second sales disappointment since its late 2023 launch.
Post A Comment:
0 comments:
Leave a comment. Thanks!